跳至主要内容
临床试验/NCT03983629
NCT03983629Unknown不适用

French National Registry of Congenital Dyserythropoietic Anemia

Lille Catholic University1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2017年2月23日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
200
试验地点
1
主要终点
Percentage of mutations

研究概览

简要总结

Congenital dyserythropoietic anemia is a heterogeneous inherited disease. Hyperplasic erythropoiesis is ineffective and associated with morphological abnormalities of some of the erythroblasts that form the basis of cytological classification. The cumulative incidence is not very clear, but varies between countries from 0.08 million in Scandinavia to 2.6 cases/million inhabitants in Italy where it appears to be the most reported.

The common manifestation is moderate chronic congenital anemia. This anaemia is either normocytic or discreetly macrocytic, non-regenerative or inappropriate regarding anaemia, contrasting with signs of hemolysis with moderate unconjugated hyperbilirubinemia. Diagnosis is usually made in the pediatric period, but because of the great heterogeneity, the diagnosis sometimes may be delayed. Splenomegaly and jaundice are mostly present. Secondary hemochromatosis is common in the absence of transfusion due to hyper-intestinal absorption of iron induced by the dyserythropoiesis.

The transmission mode for Type I and II is autosomal recessive, while it is autosomal dominant or sporadic for Type III.

Several clinical questions remain concerning this disease :

  • the median survival of patients is not well known, neither the causes of death
  • benefit/risk of splenectomy
  • iron overload quantification and consequences

The idea is to stablish a French registry of congenital dyserythropoietic anemia in order to help to understand the correlation between phenotype and genotype of this disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient with confirmed CDA
  • No opposition to the use of health data for research purposes

排除标准

  • Patient opposed to participate in the study

结局指标

主要结局

Percentage of mutations

时间窗: up to three years

Genetic analysis will be performed with whole genome and whole exome sequencing

次要结局

  • Rate of Interferon treatment efficacy(up to three years)
  • Median survival(up to three years)
  • Prevalence of different causes of death(up to three years)

研究者

发起方
Lille Catholic University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验